CoChat

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Carvalho, André F., Sharma, Manu S., Brunoni, André R., Vieta, Eduard, Fava, Giovanni A. · 2016 · Psychotherapy and Psychosomatics

The DOI matches its Crossref record; 250 of the 251 references it cites were found in a registry or an index.

Abstract

Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later. They encompass gastrointestinal symptoms (nausea, diarrhea, gastric bleeding, dyspepsia), hepatotoxicity, weight gain and metabolic abnormalities, cardiovascular disturbances (heart rate, QT interval prolongation, hypertension, orthostatic hypotension), genitourinary symptoms (urinary retention, incontinence), sexual dysfunction, hyponatremia, osteoporosis and risk of fractures, bleeding, central nervous system disturbances (lowering of seizure threshold, extrapyramidal side effects, cognitive disturbances), sweating, sleep disturbances, affective disturbances (apathy, switches, paradoxical effects), ophthalmic manifestations (glaucoma, cataract) and hyperprolactinemia. At times, such adverse events may persist after drug discontinuation, yielding iatrogenic comorbidity. Other areas of concern involve suicidality, safety in overdose, discontinuation syndromes, risks during pregnancy and breast feeding, as well as risk of malignancies. Thus, the rational selection of ADs should consider the potential benefits and risks, likelihood of responsiveness to the treatment option and vulnerability to adverse events. The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.

Overview

Integrity signals

Registry

Crossref · 10.1159/000447034

Cites

250 of 250 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

1 retracted

Research works printed but not linked: 1

  1. 10.1345/aph.1A254 · doi:10.1345/aph.1a254 · Paper page

Cited by

See all 654

Metadata

Authors
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A.
Affiliations
  • The University of Texas Health Science Center at Houston (US)
  • Universidade de São Paulo (BR)
  • Centro de Investigación Biomédica en Red de Salud Mental (ES)
  • University at Buffalo, State University of New York (US)
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2016
Volume
85
Issue
5
Pages
270-288
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2477696699
Cited by
650
References
251
Citations by year
2026: 46 · 2025: 67 · 2024: 95 · 2023: 84 · 2022: 81 · 2021: 75 · 2020: 55 · 2019: 54 · 2018: 50 · 2017: 38 · 2016: 4
FWCI
5.57
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Psychotherapy and Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Funders
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
newer antidepressants, antidepressant side effects, drug safety, tolerability, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran, vortioxetine, gastrointestinal adverse effects, hepatotoxicity, weight gain, QT prolongation, sexual dysfunction, hyponatremia, osteoporosis, paradoxical effects, suicidality, antidepressant overdose, discontinuation syndrome, pregnancy and lactation, cancer risk, drug selection
MeSH terms
Antidepressive Agents, Major Depressive Disorder, Humans, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.